MA32820B1 - Procede pour reduire la thrombocytopenie et la mortalite associee a la thrombocytopenie - Google Patents

Procede pour reduire la thrombocytopenie et la mortalite associee a la thrombocytopenie

Info

Publication number
MA32820B1
MA32820B1 MA33876A MA33876A MA32820B1 MA 32820 B1 MA32820 B1 MA 32820B1 MA 33876 A MA33876 A MA 33876A MA 33876 A MA33876 A MA 33876A MA 32820 B1 MA32820 B1 MA 32820B1
Authority
MA
Morocco
Prior art keywords
thrombocytopenia
reducing
mortality associated
risk
mortality
Prior art date
Application number
MA33876A
Other languages
Arabic (ar)
English (en)
Inventor
Marco Valgimigli
Original Assignee
Iroko Cardio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42198725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32820(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iroko Cardio Llc filed Critical Iroko Cardio Llc
Publication of MA32820B1 publication Critical patent/MA32820B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des procédés pour réduire le risque de mortalité et morbidité associé à la thrombocytopénie, et pour réduire le risque de devenir thrombocytopénique, chez des patients dont le traitement requiert l'inhibition de l'agrégation plaquettaire. Les procédés mettent en Suvre l'administration d'un sel pharmaceutiquement acceptable de tirofiban.
MA33876A 2008-11-21 2011-05-20 Procede pour reduire la thrombocytopenie et la mortalite associee a la thrombocytopenie MA32820B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11697608P 2008-11-21 2008-11-21
PCT/US2009/006240 WO2010059244A2 (fr) 2008-11-21 2009-11-20 Procédé pour réduire la thrombocytopénie et la mortalité associée à la thrombocytopénie

Publications (1)

Publication Number Publication Date
MA32820B1 true MA32820B1 (fr) 2011-11-01

Family

ID=42198725

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33876A MA32820B1 (fr) 2008-11-21 2011-05-20 Procede pour reduire la thrombocytopenie et la mortalite associee a la thrombocytopenie

Country Status (18)

Country Link
US (1) US20120059036A1 (fr)
EP (1) EP2355824A4 (fr)
KR (1) KR20110108330A (fr)
AU (1) AU2009318101A1 (fr)
BR (1) BRPI0920984A2 (fr)
CL (1) CL2011001175A1 (fr)
CO (1) CO6390039A2 (fr)
CR (1) CR20110271A (fr)
DO (1) DOP2011000149A (fr)
EC (1) ECSP11011152A (fr)
MA (1) MA32820B1 (fr)
MX (1) MX2011005376A (fr)
NI (1) NI201100101A (fr)
PE (1) PE20110946A1 (fr)
SV (1) SV2011003915A (fr)
TN (1) TN2011000256A1 (fr)
WO (1) WO2010059244A2 (fr)
ZA (1) ZA201103741B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101996880B1 (ko) 2018-03-16 2019-07-05 경성대학교 산학협력단 컴파운드 k를 유효성분으로 포함하는 혈소판 감소증 예방 또는 치료용 조성물
CN112441962A (zh) * 2019-09-04 2021-03-05 武汉武药科技有限公司 替罗非班及其纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
HUP0303917A2 (hu) * 2001-01-26 2004-03-01 Schering Corporation Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
US6770660B2 (en) 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
KR20050057294A (ko) * 2002-09-09 2005-06-16 트라이젠 리미티드 보론산 염, 및 혈전증의 치료를 위한 그것의 용도
KR20070032648A (ko) * 2004-05-12 2007-03-22 브리스톨-마이어스 스큅 컴퍼니 혈전 상태의 치료에 유용한 ｐ２ｙ１ 수용체의 우레아길항제
AU2005296305A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease

Also Published As

Publication number Publication date
WO2010059244A3 (fr) 2010-10-14
ZA201103741B (en) 2012-01-25
US20120059036A1 (en) 2012-03-08
EP2355824A4 (fr) 2012-11-07
NI201100101A (es) 2011-12-19
PE20110946A1 (es) 2012-01-05
CL2011001175A1 (es) 2011-11-11
TN2011000256A1 (en) 2012-12-17
BRPI0920984A2 (pt) 2017-07-11
AU2009318101A1 (en) 2010-05-27
KR20110108330A (ko) 2011-10-05
EP2355824A2 (fr) 2011-08-17
MX2011005376A (es) 2011-10-19
DOP2011000149A (es) 2011-10-31
CR20110271A (es) 2011-10-13
CO6390039A2 (es) 2012-02-29
SV2011003915A (es) 2011-07-01
WO2010059244A2 (fr) 2010-05-27
ECSP11011152A (es) 2011-09-30

Similar Documents

Publication Publication Date Title
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
MY153198A (en) Inhibitors of protein aggregation
BR112015020466A2 (pt) inibidores de cdc7
CL2011000513A1 (es) Metodos para reducir o inhibir la angiogenesis en un sujeto que tiene una enfermedad o condicion ocular asociada con la angiogenesis que comprende la administracion de un antagonista de tetraspanina 12(tspan12) y/o un antagonista de norrina.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2009013332A (es) Inhibidores de ire-1 alfa.
MX2016012965A (es) Metodo para preparar amg 416.
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
MD3347002T2 (ro) Tratamentul bolii Alzheimer într-o populație specifică de pacienți
WO2006092741A3 (fr) Traitement des troubles inflammatoires avec du praziquantel
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2013002418A (es) Administracion de lorcaserina a individuos con daño renal.
MX360147B (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos.
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
AR060733A1 (es) Proceso para la precipitacion y el aislamiento de compuestos de 6,6-dimetil-3-azabiciclo [3.1.0] hexanamida mediante precipitacion controlada y formulaciones farmaceuticas que contienen los mismos
MA32820B1 (fr) Procede pour reduire la thrombocytopenie et la mortalite associee a la thrombocytopenie
GB201013785D0 (en) Treatment
EA201190256A1 (ru) Способ снижения уровня убиквитинилированных белков
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
WO2010120872A3 (fr) Procédé pour abaisser les niveaux de pro-adam10 sécrétase et/ou de bêta-sécrétase
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble
MX2010003615A (es) Tratamiento de desordenes neurologicos.
FR2913419B1 (fr) Procede biologique pour le traitement des eaux usees.